Congress meeting · Dr. Tomoko Vogel

30 Jan 2026 · In person · Dr. Tomoko Vogel, Ospedale San Raffaele · MSL Rachel Adeyemi · Vantrexa

ReviewedVeeva CRMENG-0016—

Capture insight from this engagement

Location: Ospedale San Raffaele
Therapeutic area: Oncology
Country: Italy
Stakeholder tier: Tier 1
Strategic objective: Not linked
Initiative: Not linked
MSL: RARachel AdeyemiMSL, Oncology (UK & Ireland)
Product: Vantrexa (vantrelimab)

Topics discussed

Chemotherapy-free first line
PD-L1 testing turnaround
Infusion-reaction management

Scientific content used

irAE management guide

Questions raised

How should grade 2 infusion reactions be managed without steroids?

Notes

Congress meeting with pathologist at Ospedale San Raffaele. Discussed chemotherapy-free first line, pd-l1 testing turnaround, infusion-reaction management.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Share MI standard response

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 3
Strategic relevance: 5
Depth of exchange: 4
Actionability: 2

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0016

Audit history (0)

All create, update and approval events for this record

No audit events in sample data